1) Flávia Angélica Ferreira Francisco, Antonio Luis Eiras de Araújo, [...], and Daniella Braz Parente, Hepatobiliary contrast agents: differential diagnosis of focal hepatic lesions, pitfalls and other indications, Radiol Bras. 2014 Sep-Oct; 47(5): 301–309. doi: 10.1590/0100-3984.2013.1867
2) Goodwin MD, Dobson JE, Sirlin CB, et al. Diagnostic challenges and pitfalls in MR imaging with hepatocyte-specific contrast agents. Radiographics. 2011;31:1547–1568.
3) António P Matos, Fernanda Velloni, Miguel Ramalho, Mamdoh AlObaidy, Aruna Rajapaksha, Richard C, Focal liver lesions: Practical magnetic resonance imaging approach SemelkaWorld J Hepatol 2015 August 8; 7(16): 1987-2008 ISSN 1948-5182 (online)
4) Tsuboyama T, Onishi H, Kim T, Akita H, Hori M, Tatsumi M, Nakamoto A, Nagano H, Matsuura N, Wakasa K, Tomoda K: Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging - correlation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology 2010;255:824-833.
5). Petersein J, Spinazzi A, Giovagnoni A, et al. Focal liver lesions: evaluation of the efficacy of gado-benate dimeglumine in MR imaging - a multi-center phase III clinical study. Radiology. 2000; 215:727-36
6). Pirovano F, Vanzulli A, Marti-Bonmati L, et al. Evaluation of the accuracy of gadobenate dime-glumine-enhanced MR imaging in the detection and characterization of focal liver lesions. AJR Am J Roentgenol. 2000;175:1111-20.
7). Schneider G, Maas R, Schultze Kool L, et al. Low-dose gadobenate dimeglumine versus standard dose gadopentetate dimeglumine for contrast-enhanced magnetic resonance imaging of the liver: an intra-individual crossover comparison. Invest Radiol. 2003;38:85-94.